Pregnancy Registry Trial



Status:Recruiting
Conditions:Neurology, Multiple Sclerosis
Therapuetic Areas:Neurology, Other
Healthy:No
Age Range:Any
Updated:1/10/2019
Start Date:October 15, 2011
End Date:December 13, 2030
Contact:Novartis Pharmaceuticals
Phone:1-888-669-6682

Use our guide to learn which trials are right for you!

The Multi-National Pregnancy Fingolimod Exposure Registry in Multiple Sclerosis (Epidemiological Study Protocol FTY720D2404)

The purpose of the Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis
(MS) is to continuously monitor, evaluate, and assess for major and minor teratogenic effects
in the offspring of women exposed to Gilenya before (up to 8 weeks before last menstrual
period) and during pregnancy in routine clinical practice. The overall aim is to collect and
evaluate data on maternal, fetal, and infant outcomes and compare it with reference
populations.


Inclusion Criteria:

- Pregnancy and reported confirmed or suspected maternal exposure to Gilenya any time
during pregnancy or shortly before pregnancy (up to 8 weeks before LMP).

- Informed consent

Exclusion Criteria:

- There are no specific exclusion criteria for this registry.

Other protocol-defined inclusion/exclusion criteria may apply
We found this trial at
4
sites
?
mi
from
Cordoba,
Click here to add this to my saved trials
Cambridge, Massachusetts 02139
?
mi
from
Cambridge, MA
Click here to add this to my saved trials
Fort Lauderdale, Florida 33313
?
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Grand Forks, North Dakota 58201
?
mi
from
Grand Forks, ND
Click here to add this to my saved trials